Esther Chan

1 month ago | thelancet.com | Esther Chan |David Bishai |Xue Li

aDepartment of Medicine, School of Clinical Medicine, Li Ka Shing Faculty of Medicine, University of Hong Kong, Hong Kong Special Administrative Region, China bDepartment of Pharmacy Administration and Clinical Pharmacy, School of Pharmaceutical Sciences, Peking University, Beijing, China cCentre for Safe Medication Practice and Research, Department of Pharmacology and Pharmacy, Li Ka Shing Faculty of Medicine, University of Hong Kong, Hong Kong Special Administrative Region, China...

Nov 18, 2024 | mdpi.com | Esther Chan |Di Di

All articles published by MDPI are made immediately available worldwide under an open access license. No special permission is required to reuse all or part of the article published by MDPI, including figures and tables. For articles published under an open access Creative Common CC BY license, any part of the article may be reused without permission provided that the original article is clearly cited. For more information, please refer to https://www.mdpi.com/openaccess.

Oct 24, 2024 | journals.sagepub.com | s’ Note |Esther Chan |Di Di

In 2021, Forbes published an opinion titled “Could Religion Be Fueling the Gender Pay Gap?” (Webster 2021). Two years later, Le Monde, a French newspaper, published a similar opinion questioning whether religions “legitimize inequality between men and women” (Larousse 2023).

Sep 3, 2024 | nature.com | Bernice L.Z. Oh |Noriko Shimasaki |Esther Chan |Limei Poon |Louis Chai |Nina Le Bert | +12 more

T cell acute lymphoblastic leukemia (T-ALL) is difficult to treat when it relapses after therapy or is chemoresistant; the prognosis of patients with relapsed or refractory T-ALL is generally poor. We report a case series of 17 such patients who received autologous chimeric antigen receptor (CAR) T cells expressing an anti-CD7 CAR and an anti-CD7 protein expression blocker (PEBL), which prevented CAR T cell fratricide. Despite high leukemic burden and low CAR T cell dosing, 16 of the 17 patients attained minimal residual disease-negative complete remission within 1 month. The remaining patient had CD7− T-ALL cells before infusion, which persisted after infusion. Toxicities were mild: cytokine release syndrome grade 1 in ten patients and grade 2 in three patients; immune effector cell-associated neurotoxicity syndrome grade 1 in two patients. Eleven patients remained relapse-free (median follow-up, 15 months), including all nine patients who received an allotransplant. The first patient is in remission 55 months after infusion without further chemotherapy or transplantation; circulating CAR T cells were detectable for 2 years. T cells regenerating after lymphodepletion lacked CD7 expression, were polyclonal and responded to SARS-CoV-2 vaccination; CD7+ immune cells reemerged concomitantly with CAR T cell disappearance. In conclusion, autologous anti-CD7 PEBL-CAR T cells have powerful antileukemic activity and are potentially an effective option for the treatment of T-ALL. In this case series of patients with T cell acute lymphoblastic leukemia (T-ALL), therapy with CD7-directed CAR T cells that express an anti-CD7 protein expression blocker to prevent CAR T-induced fratricide showed encouraging rates of clinical response and persistence of circulating CAR T cells.

Jun 20, 2024 | e27.co | Esther Chan

Verify Your Email AddressYour account contact email hasn't been verified yet. Please verify your email addressAdd your investment information{{name}}You are part of this roundWere you a part of this investment round? No Yes Add me to this roundThis company hasn't added any fundings yet. NotesSuccess! Note is successfully saved. Error! Note is not saved.